Sponsor:
Eli Lilly and Company
Code:
NCT07928245
Conditions
Major Depressive Disorder
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Brenipatide
Placebo
Brief summary:
Conditions
Major Depressive Disorder
Study ID
NCT07928245
Start date
Nov 10, 2026
Status verified date
Nov, 2026
Completion date
Jul, 2028
Anticipated
Primary completion date
May, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
330 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Brenipatide
placebo comparator: Placebo
Interventions
Brenipatide
Placebo
Primary outcome measure
Central contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.comLocations
Inland Psychiatric Medical Group
Recruiting
Chino, California, United States, 91710
Contacts
Principal Investigator:
Nandita Puchakayala
Denali Health - Plant City, FL
Recruiting
Plant City, Florida, United States, 33563
Contacts
Principal Investigator:
Walid Aziz
Sponsor
Eli Lilly and Company
Last update posted
Nov 20, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.